In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
The Securities and Exchange Commission has been accused of "over-regulation" in recent years as it has proposed and finalized dozens of rules in a relatively short ...
It's the Summer Solstice, and that means that for most of us the sun is shining, temperatures are heating up, and longer days allow for pursuits ...
When former BlackRock executive Salim Ramji takes the helm next month at Vanguard, the asset management behemoth's board of directors also will install its first-ever independent ...
Former BNY Mellon executive Joseph Keenan spent time during the pandemic learning "all things blockchain," knowledge that has come in handy since he was tapped in ...